{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T14:10:29Z","timestamp":1795011029543,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T00:00:00Z","timestamp":1533600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006041","name":"Innovate UK","doi-asserted-by":"publisher","award":["710832"],"award-info":[{"award-number":["710832"]}],"id":[{"id":"10.13039\/501100006041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006041","name":"Innovate UK","doi-asserted-by":"publisher","award":["710832"],"award-info":[{"award-number":["710832"]}],"id":[{"id":"10.13039\/501100006041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006041","name":"Innovate UK","doi-asserted-by":"publisher","award":["710832"],"award-info":[{"award-number":["710832"]}],"id":[{"id":"10.13039\/501100006041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006041","name":"Innovate UK","doi-asserted-by":"publisher","award":["710832"],"award-info":[{"award-number":["710832"]}],"id":[{"id":"10.13039\/501100006041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1038\/s41388-018-0426-6","type":"journal-article","created":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T11:16:48Z","timestamp":1533640608000},"page":"194-208","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":194,"title":["ATP in the tumour microenvironment drives expression of nfP2X7, a key mediator of cancer cell survival"],"prefix":"10.1038","volume":"38","author":[{"given":"SM","family":"Gilbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CJ","family":"Oliphant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AL","family":"Peille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8558-0347","authenticated-orcid":false,"given":"P.","family":"Bronsert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Falzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Di Virgilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"McNulty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,7]]},"reference":[{"issue":"Suppl 1","key":"426_CR1","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1038\/sj.bjp.0706429","volume":"147","author":"G Burnstock","year":"2006","unstructured":"Burnstock G. Purinergic signalling. Br J Pharmacol. 2006;147(Suppl 1):S172\u2013181.","journal-title":"Br J Pharmacol"},{"key":"426_CR2","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1152\/physrev.00015.2002","volume":"82","author":"RA North","year":"2002","unstructured":"North RA. Molecular physiology of P2X receptors. Physiol Rev. 2002;82:1013\u201367.","journal-title":"Physiol Rev"},{"key":"426_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1146\/annurev.pharmtox.40.1.563","volume":"40","author":"RA North","year":"2000","unstructured":"North RA, Surprenant A. Pharmacology of cloned P2X receptors. Annu Rev Pharmacol Toxicol. 2000;40:563\u201380.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"426_CR4","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1126\/science.272.5262.735","volume":"272","author":"A Surprenant","year":"1996","unstructured":"Surprenant A, Rassendren F, Kawashima E, North RA, Buell G. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science. 1996;272:735\u20138.","journal-title":"Science"},{"key":"426_CR5","doi-asserted-by":"publisher","first-page":"28142","DOI":"10.1074\/jbc.M501290200","volume":"280","author":"R Auger","year":"2005","unstructured":"Auger R, Motta I, Benihoud K, Ojcius DM, Kanellopoulos JM. A role for mitogen-activated protein kinase(Erk1\/2) activation and non-selective pore formation in P2X7 receptor-mediated thymocyte death. J Biol Chem. 2005;280:28142\u201351.","journal-title":"J Biol Chem"},{"key":"426_CR6","doi-asserted-by":"publisher","first-page":"7988","DOI":"10.1073\/pnas.85.21.7988","volume":"85","author":"HP Buisman","year":"1988","unstructured":"Buisman HP, Steinberg TH, Fischbarg J, Silverstein SC, Vogelzang SA, Ince C, et al. Extracellular ATP induces a large nonselective conductance in macrophage plasma membranes. Proc Natl Acad Sci USA. 1988;85:7988\u201392.","journal-title":"Proc Natl Acad Sci USA"},{"key":"426_CR7","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.4049\/jimmunol.143.6.1955","volume":"143","author":"F Virgilio Di","year":"1989","unstructured":"Di Virgilio F, Bronte V, Collavo D, Zanovello P. Responses of mouse lymphocytes to extracellular adenosine 5\u2019-triphosphate (ATP). Lymphocytes with cytotoxic activity are resistant to the permeabilizing effects of ATP. J Immunol. 1989;143:1955\u201360.","journal-title":"J Immunol"},{"key":"426_CR8","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1091\/mbc.e04-11-1025","volume":"16","author":"E Adinolfi","year":"2005","unstructured":"Adinolfi E, Callegari MG, Ferrari D, Bolognesi C, Minelli M, Wieckowski MR, et al. Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Mol Biol Cell. 2005;16:3260\u201372.","journal-title":"Mol Biol Cell"},{"key":"426_CR9","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1158\/0008-5472.CAN-11-1947","volume":"72","author":"E Adinolfi","year":"2012","unstructured":"Adinolfi E, Raffaghello L, Giuliani AL, Cavazzini L, Capece M, Chiozzi P, et al. Expression of P2X7 receptor increases in vivo tumor growth. Cancer Res. 2012;72:2957\u201369.","journal-title":"Cancer Res"},{"key":"426_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/onc.2016.206","volume":"36","author":"F Virgilio Di","year":"2017","unstructured":"Di Virgilio F, Adinolfi E. Extracellular purines, purinergic receptors and tumor growth. Oncogene. 2017;36:293\u2013303.","journal-title":"Oncogene"},{"key":"426_CR11","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1038\/onc.2010.593","volume":"30","author":"B Jelassi","year":"2011","unstructured":"Jelassi B, Chantome A, Alcaraz-Perez F, Baroja-Mazo A, Cayuela ML, Pelegrin P, et al. P2X(7) receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness. Oncogene. 2011;30:2108\u201322.","journal-title":"Oncogene"},{"key":"426_CR12","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1182\/blood.V99.2.706","volume":"99","author":"E Adinolfi","year":"2002","unstructured":"Adinolfi E, Melchiorri L, Falzoni S, Chiozzi P, Morelli A, Tieghi A, et al. P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood. 2002;99:706\u20138.","journal-title":"Blood"},{"key":"426_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.105","volume":"3","author":"F Amoroso","year":"2012","unstructured":"Amoroso F, Falzoni S, Adinolfi E, Ferrari D, Di Virgilio F. The P2X7 receptor is a key modulator of aerobic glycolysis. Cell Death Dis. 2012;3:e370.","journal-title":"Cell Death Dis"},{"key":"426_CR14","doi-asserted-by":"publisher","first-page":"33206","DOI":"10.1074\/jbc.274.47.33206","volume":"274","author":"OR Baricordi","year":"1999","unstructured":"Baricordi OR, Melchiorri L, Adinolfi E, Falzoni S, Chiozzi P, Buell G, et al. Increased proliferation rate of lymphoid cells transfected with the P2X(7) ATP receptor. J Biol Chem. 1999;274:33206\u20138.","journal-title":"J Biol Chem"},{"key":"426_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/imr.12528","volume":"276","author":"B Allard","year":"2017","unstructured":"Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol Rev. 2017;276:121\u201344.","journal-title":"Immunol Rev"},{"key":"426_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002599","volume":"3","author":"P Pellegatti","year":"2008","unstructured":"Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F. Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS ONE. 2008;3:e2599.","journal-title":"PLoS ONE"},{"key":"426_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.immuni.2017.06.020","volume":"47","author":"F Virgilio Di","year":"2017","unstructured":"Di Virgilio F, Dal Ben D, Sarti AC, Giuliani AL, Falzoni S. The P2X7 receptor in infection and inflammation. Immunity. 2017;47:15\u201331.","journal-title":"Immunity"},{"key":"426_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51\u201372.","journal-title":"Annu Rev Immunol"},{"key":"426_CR19","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/cvr\/cvs187","volume":"95","author":"AW Lohman","year":"2012","unstructured":"Lohman AW, Billaud M, Isakson BE. Mechanisms of ATP release and signalling in the blood vessel wall. Cardiovasc Res. 2012;95:269\u201380.","journal-title":"Cardiovasc Res"},{"key":"426_CR20","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1158\/0008-5472.CAN-05-3185","volume":"66","author":"L Raffaghello","year":"2006","unstructured":"Raffaghello L, Chiozzi P, Falzoni S, Di Virgilio F, Pistoia V. The P2X7 receptor sustains the growth of human neuroblastoma cells through a substance P-dependent mechanism. Cancer Res. 2006;66:907\u201314.","journal-title":"Cancer Res"},{"key":"426_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0014-5793(03)00172-8","volume":"538","author":"JA Barden","year":"2003","unstructured":"Barden JA, Sluyter R, Gu BJ, Wiley JS. Specific detection of non-functional human P2X(7) receptors in HEK293 cells and B-lymphocytes. FEBS Lett. 2003;538:159\u201362.","journal-title":"FEBS Lett"},{"key":"426_CR22","doi-asserted-by":"publisher","first-page":"C1189","DOI":"10.1152\/ajpcell.2000.279.4.C1189","volume":"279","author":"BJ Gu","year":"2000","unstructured":"Gu BJ, Zhang WY, Bendall LJ, Chessell IP, Buell GN, Wiley JS. Expression of P2X(7) purinoceptors on human lymphocytes and monocytes: evidence for nonfunctional P2X(7) receptors. Am J Physiol Cell Physiol. 2000;279:C1189\u201397.","journal-title":"Am J Physiol Cell Physiol"},{"key":"426_CR23","doi-asserted-by":"crossref","unstructured":"Sluyter R. The P2X7 receptor. Adv Exp Med Biol 2017;1051:17\u201353.","DOI":"10.1007\/5584_2017_59"},{"key":"426_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0014-5793(01)03311-7","volume":"512","author":"RA Worthington","year":"2002","unstructured":"Worthington RA, Smart ML, Gu BJ, Williams DA, Petrou S, Wiley JS, et al. Point mutations confer loss of ATP-induced human P2X(7) receptor function. FEBS Lett. 2002;512:43\u20136.","journal-title":"FEBS Lett"},{"key":"426_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/00008390-200304000-00005","volume":"13","author":"M Slater","year":"2003","unstructured":"Slater M, Scolyer RA, Gidley-Baird A, Thompson JF, Barden JA. Increased expression of apoptotic markers in melanoma. Melanoma Res. 2003;13:137\u201345.","journal-title":"Melanoma Res"},{"key":"426_CR26","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.0309-0167.2004.01798.x","volume":"44","author":"M Slater","year":"2004","unstructured":"Slater M, Danieletto S, Gidley-Baird A, Teh LC, Barden JA. Early prostate cancer detected using expression of non-functional cytolytic P2X7 receptors. Histopathology. 2004;44:206\u201315.","journal-title":"Histopathology"},{"key":"426_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1023\/B:BREA.0000010670.85915.0f","volume":"83","author":"M Slater","year":"2004","unstructured":"Slater M, Danieletto S, Pooley M, Cheng Teh L, Gidley-Baird A, Barden JA. Differentiation between cancerous and normal hyperplastic lobules in breast lesions. Breast Cancer Res Treat. 2004;83:1\u201310.","journal-title":"Breast Cancer Res Treat"},{"key":"426_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/bjd.15364","volume":"177","author":"SM Gilbert","year":"2017","unstructured":"Gilbert SM, Gidley Baird A, Glazer S, Barden JA, Glazer A, Teh LC, et al. A phase I clinical trial demonstrates that nfP2X7 -targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma. Br J Dermatol. 2017;177:117\u201324.","journal-title":"Br J Dermatol"},{"key":"426_CR29","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/j.1476-5381.2009.00233.x","volume":"157","author":"DL Donnelly-Roberts","year":"2009","unstructured":"Donnelly-Roberts DL, Namovic MT, Han P, Jarvis MF. Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors. Br J Pharmacol. 2009;157:1203\u201314.","journal-title":"Br J Pharmacol"},{"key":"426_CR30","unstructured":"Barden JA. Anti p2x7 receptor antibodies and fragments thereof WO2011020155 A1, 2011."},{"key":"426_CR31","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood.V92.10.3521","volume":"92","author":"G Buell","year":"1998","unstructured":"Buell G, Chessell IP, Michel AD, Collo G, Salazzo M, Herren S, et al. Blockade of human P2X7 receptor function with a monoclonal antibody. Blood. 1998;92:3521\u20138.","journal-title":"Blood"},{"key":"426_CR32","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.leukres.2004.04.001","volume":"28","author":"XJ Zhang","year":"2004","unstructured":"Zhang XJ, Zheng GG, Ma XT, Yang YH, Li G, Rao Q, et al. Expression of P2X7 in human hematopoietic cell lines and leukemia patients. Leuk Res. 2004;28:1313\u201322.","journal-title":"Leuk Res"},{"key":"426_CR33","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1124\/mol.107.040725","volume":"73","author":"R Robert","year":"2008","unstructured":"Robert R, Carlile GW, Pavel C, Liu N, Anjos SM, Liao J, et al. Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol Pharmacol. 2008;73:478\u201389.","journal-title":"Mol Pharmacol"},{"key":"426_CR34","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.1038\/onc.2014.444","volume":"34","author":"F Amoroso","year":"2015","unstructured":"Amoroso F, Capece M, Rotondo A, Cangelosi D, Ferracin M, Franceschini A, et al. The P2X7 receptor is a key modulator of the PI3K\/GSK3beta\/VEGF signaling network: evidence in experimental neuroblastoma. Oncogene. 2015;34:5240\u201351.","journal-title":"Oncogene"},{"key":"426_CR35","doi-asserted-by":"publisher","first-page":"49664","DOI":"10.18632\/oncotarget.10430","volume":"7","author":"F Amoroso","year":"2016","unstructured":"Amoroso F, Salaro E, Falzoni S, Chiozzi P, Giuliani AL, Cavallesco G, et al. P2X7 targeting inhibits growth of human mesothelioma. Oncotarget. 2016;7:49664\u201376.","journal-title":"Oncotarget"},{"key":"426_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114371","volume":"9","author":"Y Qiu","year":"2014","unstructured":"Qiu Y, Li WH, Zhang HQ, Liu Y, Tian XX, Fang WG. P2X7 mediates ATP-driven invasiveness in prostate cancer cells. PLoS ONE. 2014;9:e114371.","journal-title":"PLoS ONE"},{"key":"426_CR37","doi-asserted-by":"publisher","first-page":"10120","DOI":"10.1074\/jbc.M805805200","volume":"284","author":"E Adinolfi","year":"2009","unstructured":"Adinolfi E, Callegari MG, Cirillo M, Pinton P, Giorgi C, Cavagna D. et al. Expression of the P2X7 receptor increases the Ca2+ content of the endoplasmic reticulum, activates NFATc1, andprotects from apoptosis.J Biol Chem.2009;284:10120\u20138.","journal-title":"J Biol Chem."},{"key":"426_CR38","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.3892\/etm.2015.2705","volume":"10","author":"C Tan","year":"2015","unstructured":"Tan C, Han LI, Zou L, Luo C, Liu A, Sheng X, et al. Expression of P2X7R in breast cancer tissue and the induction of apoptosis by the gene-specific shRNA in MCF-7 cells. Exp Ther Med. 2015;10:1472\u20138.","journal-title":"Exp Ther Med"},{"key":"426_CR39","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.185.3.579","volume":"185","author":"D Ferrari","year":"1997","unstructured":"Ferrari D, Chiozzi P, Falzoni S, Hanau S, Di Virgilio F. Purinergic modulation of interleukin-1 beta release from microglial cells stimulated with bacterial endotoxin. J Exp Med. 1997;185:579\u201382.","journal-title":"J Exp Med"},{"key":"426_CR40","doi-asserted-by":"publisher","first-page":"13205","DOI":"10.1074\/jbc.274.19.13205","volume":"274","author":"D Ferrari","year":"1999","unstructured":"Ferrari D, Stroh C, Schulze-Osthoff K. P2X7\/P2Z purinoreceptor-mediated activation of transcription factor NFAT in microglial cells. J Biol Chem. 1999;274:13205\u201310.","journal-title":"J Biol Chem"},{"key":"426_CR41","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1182\/blood.V87.2.682.bloodjournal872682","volume":"87","author":"OR Baricordi","year":"1996","unstructured":"Baricordi OR, Ferrari D, Melchiorri L, Chiozzi P, Hanau S, Chiari E, et al. An ATP-activated channel is involved in mitogenic stimulation of human T lymphocytes. Blood. 1996;87:682\u201390.","journal-title":"Blood"},{"key":"426_CR42","doi-asserted-by":"publisher","first-page":"17228","DOI":"10.1074\/jbc.M602999200","volume":"281","author":"YH Feng","year":"2006","unstructured":"Feng YH, Li X, Wang L, Zhou L, Gorodeski GI. A truncated P2X7 receptor variant (P2X7-j) endogenously expressed in cervical cancer cells antagonizes the full-length P2X7 receptor through hetero-oligomerization. J Biol Chem. 2006;281:17228\u201337.","journal-title":"J Biol Chem"},{"key":"426_CR43","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/nm.2028","volume":"15","author":"F Ghiringhelli","year":"2009","unstructured":"Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009;15:1170\u20138.","journal-title":"Nat Med"},{"key":"426_CR44","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1399-0039.2011.01780.x","volume":"78","author":"JS Wiley","year":"2011","unstructured":"Wiley JS, Sluyter R, Gu BJ, Stokes L, Fuller SJ. The human P2X7 receptor and its role in innate immunity. Tissue Antigens. 2011;78:321\u201332.","journal-title":"Tissue Antigens"},{"key":"426_CR45","doi-asserted-by":"publisher","first-page":"237","DOI":"10.4172\/2155-9899.1000237","volume":"5","author":"JA Barden","year":"2014","unstructured":"Barden JA, Yuksel A, Pedersten J, Danieletto S, Delprado W. Non-functional P2X7: a novel and ubiquitous target in human cancer. J Clin Cell Immunol. 2014;5:237.","journal-title":"J Clin Cell Immunol"},{"key":"426_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2002-3-7-research0034","volume":"3","author":"J Vandesompele","year":"2002","unstructured":"Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:RESEARCH0034.","journal-title":"Genome Biol"},{"key":"426_CR47","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1172\/JCI117770","volume":"95","author":"S Falzoni","year":"1995","unstructured":"Falzoni S, Munerati M, Ferrari D, Spisani S, Moretti S, Di Virgilio F. The purinergic P2Z receptor of human macrophage cells. Characterization and possible physiological role. J Clin Invest. 1995;95:1207\u201316.","journal-title":"J Clin Invest"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0426-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0426-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0426-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T06:11:12Z","timestamp":1693807872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-018-0426-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,7]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["426"],"URL":"https:\/\/doi.org\/10.1038\/s41388-018-0426-6","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,7]]},"assertion":[{"value":"15 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SMG, CJO, SM and RL are employees of Biosceptre (UK) Limited, a company commercialising nfP2X7-targeted therapies. ALP and PB were contracted by Biosceptre (UK) Limited as part of Charles River Discovery Research Services Germany GmbH (formerly named Oncotest GmbH). SH is BBSRC CASE PhD student partly funded by Biosceptre (UK) Limited. FDV serves as a member of Biosceptre International Limited\u2019s Scientific Advisory Board. SF has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}